transcription elongation factor A like 1Genealiases: HIJRS · NEDGFAX · SIIR · WEX9 · p21 · pp21
Q-omics provides the consensus-scored TCEAL1 profile across patient tissues and cancer cell-line models. TCEAL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TCEAL1 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, TCEAL1 protein abundance shows 24,616 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, KICH, and UCEC as cancer lineages where TCEAL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEAL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEAL1 survival associations across molecular data types. TCEAL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEAL1 RNA expression–survival associations across cancer types. High TCEAL1 expression shows unfavorable associations in UVM, SCLC and KIRP, but favorable associations in KIRC, MESO and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TCEAL1 RNA expression.
This table summarizes TCEAL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TCEAL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEAL1 shows lower tumor expression in KICH, THCA, BLCA, LUSC and LUAD and higher tumor expression in LIHC. The KICH box plot shows higher TCEAL1 RNA expression in normal versus tumor tissue (log2 FC = −1.756, t-test p < 0.001).
This table shows molecular features associated with TCEAL1 in patient tissues and cancer cell lines. In patient samples, TCEAL1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEAL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
